Targeted Limbic Self-modulation as a Potential Treatment for Patients Suffering From Fibromyalgia

Fibromyalgia (FM) Clinical Trial

Official title:

Mechanistic Perspective on EEG Based Amygdala Driven NF in Fibromyalgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02146495
• Other study ID #: TASMC-14-HS-0044-CTIL
• Status: Completed
• Phase: N/A
• Start date: January 2017
• Est. completion date: August 2022

Study information

• Verified date: February 2024
• Source: Tel-Aviv Sourasky Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to test whether voluntary regulation of limbic system activation is possible in patients with fibromyalgia and to examine the neurobehavioral effects of specific neuromodulation of this circuit on somatosensory, limbic, and cognitive processes. This goal will be achieved by using a method previously developed for the construction of an fMRI-enriched EEG model ("EEG-Finger-Print", EFP) that selectively targets the amygdala BOLD activation (Amyg-EFP). The investigators conducted two studies: In the first study, the investigators conducted simultaneous recordings of EEG and fMRI during Amyg-EFP NF training on patients with FM. The main objective is to demonstrate target engagement following Amyg-EFP-NF training in FM patients. In the second study, the investigators aim to conduct a randomized clinical trial to examine the causal effect of the Amyg-EFP NF trial. The investigators will compare neurobehavioral effects between three groups. I. Amyg-EFP-NF group: a multisession NF trial using the Amyg-EFP model. II. Control group 1- sham-NF: a multisession NF trial using sham feedback. III. Control group 2: patients in this group will continue their usual treatment without intervention.

Description:

The current study aims to focus on the neural mechanism and brain-guided therapy of Fibromyalgia (FM); a chronic pain syndrome. Despite intense investigations, the pathophysiology of fibromyalgia remains elusive. Several studies demonstrated that morphological and functional changes in the central nervous system may play an important role in FM development and progression. The unknown etiopathology of FM contributed greatly to the absence of mechanism-specific cures. The insufficient treatment for FM, along with the understanding that CNS abnormality constitutes a major factor in FM pathophysiology, emphasizes the need for mechanism-based therapeutic intervention and opens the door for advanced neuromodulation techniques. Guided by this approach, the investigators aspired to establish a multi-function model with the potential to exert neuromodulation effects. To address this goal, the investigators employ a method previously developed for the construction of an fMRI-enriched EEG model ("EEG-Finger-Print", EFP). In this approach, EEG is used to predict specific brain activity, as measured by fMRI in a given region. Our main objective is to explore the neural mechanisms that underlie limbic neuromodulation and to gain a profound understanding of the functional processes that can potentially modify deficient functions in FM. The investigators intend to conduct two studies. In the first study, the investigators focus on the previously developed EFP model that selectively targets the amygdala BOLD activation (Amyg-EFP). The investigators aspired to investigate Amyg-EFP-NF effects on chronic pain in FM. To do so, the investigators conducted simultaneous recordings of EEG and fMRI during Amyg-EFP NF training on patients with FM. The main research objective of this study is to demonstrate target engagement following Amyg-EFP-NF training in FM patients. In the second study, the investigators aim to conduct a randomized clinical trial to examine the causal effect of the Amyg-EFP on patients with FM and to explore the clinical effect of this model on a wide range of symptoms related to FM. To examine the neural, clinical, and behavioral specific effects of the EFP-NF training, the investigators will implement a comprehensive clinical assessment. Furthermore, the investigators will conduct an MRI/fMRI scan before and after the EFP-NF trial, in order to explore the neural modification effects. Clinical follow-up will be conducted after 10-12 months from the post-intervention evaluation. The investigators will compare the neural, clinical, and behavioral effects between three groups. I. Amyg-EFP-NF group: a multisession NF trial using feedback driven by the Amyg-EFP model. II. Control group I- sham-NF: a multisession NF trial using sham feedback. III. Control group II: patients in this group will continue their usual treatment without any intervention. The investigators hypothesize that patients in the Amyg -EFP-NF group will exhibit wider and more robust changes in neural and behavioral outcomes associated with the wide range of symptoms related to FM. This study can significantly advance the understanding of the neural processes that mediate modification of somatic-affective functions in patients with FM and, therefore, enable the establishment of better treatment prediction and possibly more personalized procedures in future studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Age: 18-55

• Fibromyalgia diagnosis by a specialist in internal medicine, Neurology or Pain medicine

• Subjective complaints about sleep disorder

• Pain does not stop despite regular medication- at least three events per week of pain ranked five out of ten

• chronic drug treatment should not be change in the near future (6 weeks).

• Hebrew speaker

• Accepted criteria for MRI scan for medical use will be followed, according to the procedures prescribed in the MRI institute of the Tel-Aviv Sourasky medical center.

Exclusion Criteria:

• Non-Hebrew speakers

• Diagnosis of another pain chronic syndrome or any significant medical illness.

• History of psychiatric or neurological diseases requiring hospitalization.

Related Conditions & MeSH terms

• Fibromyalgia
• Fibromyalgia (FM)
• Myofascial Pain Syndromes

Intervention

Device:
• Simultaneous EEG and fMRI recordings

• Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Trial
Neurofeedback training utilizing Amygdala Electrical Fingerprint (Amyg-EFP) methodology
• Amygdala-Electrical Fingerprint (Amyg-EFP)-NF Sham Trial
Sham neurofeedback training based on a randomized artificial Amyg-EFP signal.

Locations

Country	Name	City	State
Israel	Tel Aviv Sourasky Medical Center	Tel Aviv	N/A = Not Applicable

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Brain pattern Changes	Measured via real-time fMRI; region of interest analysis in the amygdala; comparison between post vs pre scans: change in blood-oxygen-level-dependent (BOLD) response to regulate > baseline condition during NF task.	Change in neural pattern immediately post-intervention relative to the baseline level (Post-intervention vs. Baseline)
Other	Amyg-EFP-NF regulation success	Measured by change in Amyg-EFP power; based on the difference between regulate and baseline conditions during the neurofeedback cycles	1-10 weeks
Other	Pain Assessment	Quantitative Sensory Testing (QST)- which assesses somatosensory function and provides thermal pain thresholds and sensory threshold.	Change in pain level immediately post-intervention relative to the baseline level (Post-intervention vs. Baseline)
Other	Sleep assessment	The investigators were measured via one-night sleep monitoring using the WatchPAT-200 device.; While the specific range scores for sleep latency and sleep efficiency using the WatchPAT-200 are not explicitly detailed in the available documentation, it's generally accepted in sleep studies that normal sleep efficiency is considered to be 85% or higher. Normal sleep onset latency typically ranges from 10 to 25 minutes.; To evaluate sleep quality, the investigators calculate a combined score using two sleep metrics: sleep latency and sleep efficiency.	Change in sleep quality immediately post-intervention relative to the baseline level (Post-intervention vs. Baseline)
Primary	Clinical improvement using the Fibromyalgia Impact Questionnaire (FIQ) to evaluate FM symptoms	Scoring from 0 (no impairment) to 80 (maximum), with subscales ranging up to 10 (maximum).	Immediately post-intervention relative to the baseline level
Primary	Clinical improvement using the Symptom Severity Score (SSS)	Ranges from 0 to 12 (highest severity).	Immediately post-intervention relative to the baseline level
Primary	Clinical improvement using the Widespread Pain Index (WPI)	Ranges from 0 to 19 (highest level of pain distribution).	Immediately post-intervention relative to the baseline level
Primary	Clinical improvement using the SF-36 Health Survey (SF-36) to evaluate daily impacts of FM	Scores from 0 to 100 (higher scores indicate better health).	Immediately post-intervention relative to the baseline level
Primary	Clinical improvement using the Trait Anxiety Inventory (STAI-T) to evaluate the level of anxiety	Ranges from 20 to 80 (highest anxiety level).	Immediately post-intervention relative to the baseline level
Primary	Clinical improvement using the Beck Depression Inventory (BDI) to evaluate the level of depression	Ranges from 0 to 63 (highest depression level).	Immediately post-intervention relative to the baseline level
Primary	Long-term clinical improvement using the Fibromyalgia Impact Questionnaire (FIQ) to evaluate FM symptoms	Scoring from 0 (no impairment) to 80 (maximum), with subscales ranging up to 10 (maximum).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Primary	Long-term clinical improvement using the Symptom Severity Score (SSS)	Ranges from 0 to 12 (highest severity).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Primary	Long-term clinical improvement using the Widespread Pain Index (WPI)	Ranges from 0 to 19 (highest level of pain distribution).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Primary	Long-term clinical improvement using the SF-36 Health Survey (SF-36) to evaluate daily impacts of FM	Scores from 0 to 100 (higher scores indicate better health).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Primary	Long-term clinical improvement using the Trait Anxiety Inventory (STAI-T) to evaluate the level of anxiety	Ranges from 20 to 80 (highest anxiety level).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Primary	Long-term clinical improvement using the Beck Depression Inventory (BDI) to evaluate the level of depression	Ranges from 0 to 63 (highest depression level).	Change in symptoms at 10-12 months relative to the baseline level (Follow-up measure vs. Baseline)
Secondary	Neural Prediction	Simultaneous fMRI/EEG scan in order to identify whether the Amyg-EFP signal reliably predicts the amygdala BOLD activity	Through study completion, an average of 2 year